Literature DB >> 25619830

Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway.

C Visciano1, F Liotti1, N Prevete2, G Cali'1, R Franco3, F Collina3, A de Paulis2, G Marone2, M Santoro1, R M Melillo1.   

Abstract

There is increasing evidence that mast cells (MCs) and their mediators are involved in the remodeling of the tumor microenvironment and promote tumor growth, angiogenesis and metastasis. We have found that an increased density of MCs in thyroid cancer (TC) correlates with enhanced invasiveness. However, the MC-derived factors responsible for this activity and the mechanisms by which they enhance TC invasiveness remain unidentified. Here, we report that MCs, when activated by TC cells, produce soluble factors that induce epithelial-to-mesenchymal transition (EMT) and stemness features of TC cells. We identified CXCL8/interleukin (IL)-8 as the main mediator contained in activated MC conditioned media (CM) capable of inducing both EMT and stemness of TC cells. Mechanistically, MC CM or exogenous IL-8 stimulated Akt phosphorylation and Slug expression in TC cells. The inhibition of the Akt pathway or depletion of the Slug transcription factor by RNA interference, reverted EMT and stemness responses. TC cells stably transfected with exogenous IL-8 underwent EMT, displayed increased stemness and enhanced tumorigenicity with respect to control cells. The analysis of TC surgical specimens by immunohistochemical analysis demonstrated a positive correlation between MC density (Tryptase(+) cells) and stemness features (OCT4 staining). Taken together, our data identify an MC-dependent IL-8-Akt-Slug pathway that sustains EMT/stemness of TC cells. The blockade of this circuit might be exploited for the therapy of advanced TC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25619830     DOI: 10.1038/onc.2014.441

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  39 in total

1.  Mast cells have a protumorigenic role in human thyroid cancer.

Authors:  R M Melillo; V Guarino; E Avilla; M R Galdiero; F Liotti; N Prevete; F W Rossi; F Basolo; C Ugolini; A de Paulis; M Santoro; G Marone
Journal:  Oncogene       Date:  2010-08-23       Impact factor: 9.867

Review 2.  The pluripotency regulator Oct4: a role in somatic stem cells?

Authors:  Christopher J Lengner; G Grant Welstead; Rudolf Jaenisch
Journal:  Cell Cycle       Date:  2008-01-14       Impact factor: 4.534

Review 3.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

4.  Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer.

Authors:  Matthew A Nehs; Carmelo Nucera; Sushruta S Nagarkatti; Peter M Sadow; Dieter Morales-Garcia; Richard A Hodin; Sareh Parangi
Journal:  Endocrinology       Date:  2011-12-27       Impact factor: 4.736

5.  Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma.

Authors:  Wei Qing; Wei-Yuan Fang; Lei Ye; Li-Yun Shen; Xiao-Fang Zhang; Xiao-Chun Fei; Xi Chen; Wei-Qing Wang; Xiao-Ying Li; Jia-Cheng Xiao; Guang Ning
Journal:  Thyroid       Date:  2012-08-07       Impact factor: 6.568

6.  Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas.

Authors:  Darya Buehler; Heather Hardin; Weihua Shan; Celina Montemayor-Garcia; Patrick S Rush; Sofia Asioli; Herbert Chen; Ricardo V Lloyd
Journal:  Mod Pathol       Date:  2012-08-17       Impact factor: 7.842

Review 7.  Multiple control of interleukin-8 gene expression.

Authors:  Elke Hoffmann; Oliver Dittrich-Breiholz; Helmut Holtmann; Michael Kracht
Journal:  J Leukoc Biol       Date:  2002-11       Impact factor: 4.962

8.  TWIST1 plays a pleiotropic role in determining the anaplastic thyroid cancer phenotype.

Authors:  Paolo Salerno; Ginesa Garcia-Rostan; Sara Piccinin; Tammaro Claudio Bencivenga; Gennaro Di Maro; Claudio Doglioni; Fulvio Basolo; Roberta Maestro; Alfredo Fusco; Massimo Santoro; Giuliana Salvatore
Journal:  J Clin Endocrinol Metab       Date:  2011-03-09       Impact factor: 5.958

Review 9.  Metastatic mechanisms in follicular cell-derived thyroid cancer.

Authors:  John E Phay; Matthew D Ringel
Journal:  Endocr Relat Cancer       Date:  2013-10-14       Impact factor: 5.678

10.  SCF(β-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2.

Authors:  Shavali Shaik; Carmelo Nucera; Hiroyuki Inuzuka; Daming Gao; Maija Garnaas; Gregory Frechette; Lauren Harris; Lixin Wan; Hidefumi Fukushima; Amjad Husain; Vania Nose; Guido Fadda; Peter M Sadow; Wolfram Goessling; Trista North; Jack Lawler; Wenyi Wei
Journal:  J Exp Med       Date:  2012-06-18       Impact factor: 14.307

View more
  85 in total

Review 1.  The immune network in thyroid cancer.

Authors:  Maria Rosaria Galdiero; Gilda Varricchi; Gianni Marone
Journal:  Oncoimmunology       Date:  2016-03-30       Impact factor: 8.110

Review 2.  Epithelial-mesenchymal transition and inflammation at the site of the primary tumor.

Authors:  Charli Dominguez; Justin M David; Claudia Palena
Journal:  Semin Cancer Biol       Date:  2017-08-18       Impact factor: 15.707

Review 3.  Eosinophils: The unsung heroes in cancer?

Authors:  Gilda Varricchi; Maria Rosaria Galdiero; Stefania Loffredo; Valeria Lucarini; Giancarlo Marone; Fabrizio Mattei; Gianni Marone; Giovanna Schiavoni
Journal:  Oncoimmunology       Date:  2017-11-13       Impact factor: 8.110

4.  Targeting tumor-resident mast cells for effective anti-melanoma immune responses.

Authors:  Susanne Kaesler; Florian Wölbing; Wolfgang Eberhard Kempf; Yuliya Skabytska; Martin Köberle; Thomas Volz; Tobias Sinnberg; Teresa Amaral; Sigrid Möckel; Amir Yazdi; Gisela Metzler; Martin Schaller; Karin Hartmann; Benjamin Weide; Claus Garbe; Hans-Georg Rammensee; Martin Röcken; Tilo Biedermann
Journal:  JCI Insight       Date:  2019-10-03

5.  Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer.

Authors:  Charli Dominguez; Kristen K McCampbell; Justin M David; Claudia Palena
Journal:  JCI Insight       Date:  2017-11-02

Review 6.  Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy.

Authors:  Nisha Nagarsheth; Max S Wicha; Weiping Zou
Journal:  Nat Rev Immunol       Date:  2017-05-30       Impact factor: 53.106

7.  The AMPK-activator AICAR in thyroid cancer: effects on CXCL8 secretion and on CXCL8-induced neoplastic cell migration.

Authors:  O Awwad; F Coperchini; P Pignatti; M Denegri; S Massara; L Croce; C A Di Buduo; V Abbonante; A Balduini; L Chiovato; M Rotondi
Journal:  J Endocrinol Invest       Date:  2018-03-15       Impact factor: 4.256

Review 8.  Epithelial-to-mesenchymal transition in thyroid cancer: a comprehensive review.

Authors:  Heewa Shakib; Sadegh Rajabi; Mohammad Hossien Dehghan; Farideh Jalali Mashayekhi; Nahid Safari-Alighiarloo; Mehdi Hedayati
Journal:  Endocrine       Date:  2019-08-04       Impact factor: 3.633

9.  EDAG-1 promotes proliferation and invasion of human thyroid cancer cells by activating MAPK/Erk and AKT signal pathways.

Authors:  Dan-Lei Chen; Zhong-Qian Hu; Xian-Fang Zheng; Xin-Yi Wang; You-Zhi Xu; Wen-Qing Li; Hao-Shu Fang; Lixin Kan; Si-Ying Wang
Journal:  Cancer Biol Ther       Date:  2016-03-02       Impact factor: 4.742

Review 10.  Mast Cell-Targeted Strategies in Cancer Therapy.

Authors:  Michele Ammendola; Rosario Sacco; Giuseppe Sammarco; Maria Luposella; Rosa Patruno; Cosmo Damiano Gadaleta; Giovambattista De Sarro; Girolamo Ranieri
Journal:  Transfus Med Hemother       Date:  2016-03-09       Impact factor: 3.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.